Ypsomed Holding AG and BD (Becton, Dickinson and Company) have announced an expanded partnership to address the rapidly growing biologics market. Building on their successful collaboration with the BD Neopak XtraFlow 2.25mL Glass Prefillable Syringe and YpsoMate 2.25 autoinjector, the companies are now developing a 5.5 mL version of the BD Neopak XtraFlow syringe. This new product is designed to be fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform, offering pharmaceutical companies and patients more options for large-volume subcutaneous self-injections. The collaboration aims to accelerate and de-risk the development of combination products, supporting innovation in self-administration for high-dose therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ypsomed Holding AG published the original content used to generate this news brief on January 21, 2026, and is solely responsible for the information contained therein.